ECSP11011192A - Formulación de anticuerpo - Google Patents

Formulación de anticuerpo

Info

Publication number
ECSP11011192A
ECSP11011192A EC2011011192A ECSP11011192A ECSP11011192A EC SP11011192 A ECSP11011192 A EC SP11011192A EC 2011011192 A EC2011011192 A EC 2011011192A EC SP11011192 A ECSP11011192 A EC SP11011192A EC SP11011192 A ECSP11011192 A EC SP11011192A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical formulations
antibody
formulation
novel pharmaceutical
agglomerates
Prior art date
Application number
EC2011011192A
Other languages
English (en)
Spanish (es)
Inventor
Hans Joachim Wallny
Joachim Momm
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011192(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP11011192A publication Critical patent/ECSP11011192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EC2011011192A 2008-12-10 2011-07-08 Formulación de anticuerpo ECSP11011192A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation

Publications (1)

Publication Number Publication Date
ECSP11011192A true ECSP11011192A (es) 2011-08-31

Family

ID=40637230

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011192A ECSP11011192A (es) 2008-12-10 2011-07-08 Formulación de anticuerpo

Country Status (31)

Country Link
US (3) US20110236398A1 (enExample)
EP (4) EP2196476A1 (enExample)
JP (6) JP6143416B2 (enExample)
KR (2) KR20170044211A (enExample)
CN (3) CN104399076B (enExample)
AU (1) AU2009324371B2 (enExample)
BR (1) BRPI0922730A2 (enExample)
CA (1) CA2745938C (enExample)
CL (1) CL2011001406A1 (enExample)
CO (1) CO6361952A2 (enExample)
CY (2) CY1117735T1 (enExample)
DK (2) DK3072906T3 (enExample)
EC (1) ECSP11011192A (enExample)
ES (2) ES2900624T3 (enExample)
HR (2) HRP20211899T1 (enExample)
HU (2) HUE028408T2 (enExample)
IL (3) IL264316B2 (enExample)
LT (1) LT3072906T (enExample)
MA (1) MA33023B1 (enExample)
MX (1) MX2011006242A (enExample)
MY (2) MY157772A (enExample)
NZ (1) NZ592918A (enExample)
PE (1) PE20120342A1 (enExample)
PL (2) PL2376533T3 (enExample)
PT (2) PT2376533T (enExample)
RU (2) RU2745601C2 (enExample)
SI (2) SI3072906T1 (enExample)
SM (1) SMT201600222B (enExample)
TN (1) TN2011000229A1 (enExample)
WO (1) WO2010066762A1 (enExample)
ZA (1) ZA201103362B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
SG183443A1 (en) 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX2012013586A (es) 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8795658B2 (en) 2010-09-17 2014-08-05 Baxter International Inc. Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
AP2014007680A0 (en) 2011-12-02 2014-06-30 Novartis Ag Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
JP6345123B2 (ja) * 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
PT2825037T (pt) * 2012-03-16 2019-08-07 Regeneron Pharma Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
HK1208231A1 (en) * 2012-09-20 2016-02-26 Morphosys Ag Treatment for rheumatoid arthritis
WO2014078502A1 (en) * 2012-11-16 2014-05-22 Novartis Ag Use of il-1 beta binding antibodies for treating peripheral arterial disease
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
UY35460A (es) 2013-03-15 2014-10-31 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015181757A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
BR112017003419A2 (pt) * 2014-09-03 2017-11-28 Medimmune Ltd formulação de anticorpo anti-il-4r-alfa estável
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
DK3386541T3 (da) 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
CN109415440B (zh) * 2016-06-27 2022-12-06 莫佛塞斯公司 抗-cd19抗体制剂
AU2017298656A1 (en) * 2016-07-21 2019-02-07 Novartis Ag Use of the IL-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
KR102546471B1 (ko) * 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
SG10201912529SA (en) 2016-11-18 2020-02-27 Astellas Pharma Inc Novel anti-human muc1 antibody fab fragment
KR20200019865A (ko) * 2017-06-22 2020-02-25 노파르티스 아게 암 치료에 사용하기 위한 il-1베타 결합 항체
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
MX2020002813A (es) * 2017-09-13 2020-07-21 Novartis Ag Uso de anticuerpos de union a il-1b para el tratamiento de la hepatitis alcoholica.
WO2019180261A1 (en) * 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
MX2020012351A (es) 2018-05-17 2021-01-29 Astellas Pharma Inc Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
EP3865154A4 (en) 2018-10-10 2022-11-09 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
SG11202108627SA (en) * 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
US20240052026A1 (en) * 2020-12-22 2024-02-15 Bio-Thera Solutions, Ltd. Stable antibody formulation, preparation method therefor, and applications thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CN101525384A (zh) 2000-06-29 2009-09-09 艾博特公司 双特异性抗体及其制备方法和用途
WO2002011753A1 (en) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
HRP20050934B1 (hr) * 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
KR20070107079A (ko) * 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
WO2006096461A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
PL2848258T3 (pl) 2005-10-26 2018-06-29 Novartis Ag Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
BRPI0721097A2 (pt) * 2006-12-11 2014-07-01 Hoffmann La Roche Formulação parenteral de anticorpo abeta
WO2008116103A2 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
DK3072906T3 (da) 2021-12-13
EP3072906B1 (en) 2021-09-08
JP2026021446A (ja) 2026-02-10
SI2376533T1 (sl) 2016-07-29
US20120315285A1 (en) 2012-12-13
IL212922B (en) 2019-02-28
SMT201600222B (it) 2016-08-31
ES2900624T3 (es) 2022-03-17
US20110236398A1 (en) 2011-09-29
EP3792282A1 (en) 2021-03-17
EP3072906A1 (en) 2016-09-28
RU2011127913A (ru) 2013-01-20
JP2018168158A (ja) 2018-11-01
AU2009324371A1 (en) 2011-06-23
IL276622A (en) 2020-09-30
MA33023B1 (fr) 2012-02-01
IL212922A0 (en) 2011-07-31
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
US8623367B2 (en) 2014-01-07
PT3072906T (pt) 2021-12-14
RU2015132431A3 (enExample) 2018-12-24
EP2376533B1 (en) 2016-03-30
CN104399076A (zh) 2015-03-11
CN102245639B (zh) 2014-12-24
WO2010066762A1 (en) 2010-06-17
CO6361952A2 (es) 2012-01-20
PT2376533T (pt) 2016-07-13
AU2009324371B2 (en) 2013-10-10
TN2011000229A1 (en) 2012-12-17
KR20120009421A (ko) 2012-01-31
CA2745938A1 (en) 2010-06-17
KR101762966B1 (ko) 2017-07-31
MY166050A (en) 2018-05-22
CL2011001406A1 (es) 2012-03-30
CN114225022A (zh) 2022-03-25
LT3072906T (lt) 2021-12-27
HRP20211899T1 (hr) 2022-03-04
CA2745938C (en) 2018-04-24
IL264316B2 (en) 2024-01-01
CY1117735T1 (el) 2017-05-17
CN104399076B (zh) 2021-09-14
ZA201103362B (en) 2012-01-25
IL264316B1 (en) 2023-09-01
CN102245639A (zh) 2011-11-16
BRPI0922730A2 (en) 2018-11-06
KR20170044211A (ko) 2017-04-24
SI3072906T1 (sl) 2022-01-31
RU2563179C2 (ru) 2015-09-20
JP7286595B2 (ja) 2023-06-05
RU2015132431A (ru) 2018-12-24
EP2376533A1 (en) 2011-10-19
US20200384108A1 (en) 2020-12-10
PL2376533T3 (pl) 2016-09-30
JP2012511540A (ja) 2012-05-24
IL264316A (en) 2019-02-28
JP2015231997A (ja) 2015-12-24
JP2020203889A (ja) 2020-12-24
EP2196476A1 (en) 2010-06-16
HK1159130A1 (zh) 2012-07-27
CY1124844T1 (el) 2022-11-25
HRP20160754T1 (hr) 2016-08-12
MX2011006242A (es) 2011-06-24
HUE028408T2 (en) 2016-12-28
PE20120342A1 (es) 2012-04-24
HUE056626T2 (hu) 2022-02-28
JP2023109938A (ja) 2023-08-08
RU2745601C2 (ru) 2021-03-29
ES2579835T3 (es) 2016-08-17
PL3072906T3 (pl) 2022-01-24
JP6143416B2 (ja) 2017-06-07
DK2376533T3 (en) 2016-06-27

Similar Documents

Publication Publication Date Title
ECSP11011192A (es) Formulación de anticuerpo
CY1125697T1 (el) Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων
AR111455A1 (es) Formulación estable de anticuerpo
PH12014502778B1 (en) Antibody formulation
CL2015001959A1 (es) (divisional solicitud 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos
AR079556A1 (es) Formacion de anticuerpos
CR20120475A (es) Mezclas pesticidas
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2013002597A (es) Arilpirrolidinas pesticidas.
CO7101240A2 (es) Compuestos ß-lactámicos sustituidos con amidina, su preparación y uso como agentes bacterianos
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
NZ705109A (en) Antibody formulations and uses thereof
MX382443B (es) Una formulación estable para usarse en el tratamiento de la enfermedad por leucodistrofia metacromática (mld).
MX357936B (es) Formulaciones de la solución de los anticuerpos anti-il-23p19 manipulados genéticamente.
ECSP13012666A (es) Formulacion en comprimidos difusibles y flotantes de un pesticida
MX385093B (es) Formulaciones de espuma y aparatos para su suministro.
NI201200157A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
BR112013009415A2 (pt) composto de éter arilóxidihalo-propenil e uso destes
CO6321223A2 (es) Formulacion farmaceutica solida que contiene ciclostazol
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
TR200806300A2 (tr) Çözünürlük artırıcı farmasötlk formulasyon
CR20150594A (es) N-(2-fluoro-2-fenetil)carboxamidas como nematicidas y endoparasiticidas
ES2604837T3 (es) Formulación de liberación sostenida que contiene anticuerpos para administración ocular